Patent SG-11201901427R-A (SG)
Title: Immunosuppressive composition for use in treating immunological disorders
Inventor: FAN XIUBO
IPC: C07K16/24
Filed: 2017-08-18
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 0 11101 HOE HI 1 0 01111 001111111 0101101111101111 0E111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/034620 Al 22 February 2018 (22.02.2018) WIP0 I PCT (51) International Patent Classification: (72) Inventors: FAN, Xiubo; Office 1, level 9, Discovery A61K 39/395 (2006.01) A61K 38/20 (2006.01) Tower, Academia Department of Clinical Translational C07K 16/24 (2006.01) A61P 3/00 (2006.01) Research, Singapore General Hospital, Singapore 169856 A61K 38/19 (2006.01) A61P 3/06 (2006.01) (SG). HWANG, William Ying Khee; Level 3, Discovery (21) International Application Number: Tower, Academia Department of Haematology, Singapore PCT/SG2017/050408 General Hospital, Singapore 169856 (SG). (22) International Filing Date: (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; 18 August 2017 (18.08.2017) P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 10201606949Q 19 August 2016 (19.08.2016) SG CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant: SINGAPORE HEALTH SERVICES PTE HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, LTD [SG/SG]; 31 Third Hospital Avenue, #03-03, Bowyer KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Block C, Singapore 168753 (SG). MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: IMMUNOSUPPRESSWE COMPOSITION FOR USE IN TREATING IMMUNOLOGICAL DISORDERS = FIG.9 = = A B a = -• dPBS 100 \"-r— tl-ii _ E 0 ° Ta 4 w 0 2 -a- 2F .CXCL5 anti-CCL24 'E [_. '6' ..-8, $0- T 40 _ 20- .1, '\"- — L_, L____ `---t_ -.• dPEIS -I- CXCL5 — anti-CCL24 0 a = 9 12 15 la 2 24 21 30 33 36 0 3 6 9 12 15 la 21 24 27 30 33 36 = Time post-injection (day) Time post-injection (day) = C 0 — -. dPBS SQ4 ' = tIS = 6 4- CXCL5 an ti -CCL24 Jr—F——i.- \"V Sot ', a ,, I— 4.> = VI 4 = LI 2F ,r tiZ > '5 -' dPBS C = CI 2 t CO 2C ., 4- 2F -I- CXCL5 -4- ant-CCL24 _ 0 3 6 9 12 15 1B 21 24 27 3O 33 36 post-injection (day) 1-1 .4 N (57) : The present disclosure describes a pharmaceutical composition of cytokines selected from Macrophage colony-stimulating factor (M-CSF), 7r (CCL24) and at least one mesenchymal stromal cell-derived protein selected fn CCL7 (MCP-3), CCL8 (MCP-2), CCL20 (MIP-3a), CXCL5 (ENA-78), 0 —. embodiment, a composition comprising anti-CCL24 antibody and CXCL5 GC of said pharmaceutical composition for treating immunological diseases, 1-1 c;;;;) discloses the use of the pharmaceutical composition for immunomodulation. ei 3 6 9 12 15 1 21 24 27 3Q 73 3£i Time Time post-injection (day) comprising at least one antibody targeting one or more lnterleukin-1 beta (IL-1 (3), CCL-1 (I- 309) and Eotaxin-2 from Prostaglandin E2 (PGE2), Osteoprotegerin (OPG), Interleukin 10 (IL-10) and CXCL6 (GCP-2). In a preferred is disclosed. The present disclosure also describes the use for example alloimmune or autoimmune diseases and further C [Continued on next page] WO 2018/034620 Al MIDEDIMOMOIDEIREEMOOMMORRIONIONVOIMIE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))